Buy Indoco Remedies; target of Rs 82: Angel Broking

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Angel Broking is bullish on Indoco Remedies and has recommended buy rating on the stock with a target of Rs 82 in its June 1, 2012 research report.

“For 4QFY2012, Indoco Remedies (Indoco) declared in-line results at the revenue front, reporting growth of 22.6% yoy. However, on the net profit front, growth came in lower than expected, growing by only 3.0% yoy. This was mainly on account of lower than expected other income. The domestic formulation segment grew by 13.4% yoy during the quarter, contributing 55.5% to the total revenue, whereas formulations exports increased by 49.0% yoy. We recommend Buy on the stock.”

“Indoco reported net sales of Rs148cr (Rs120cr), up 22.6% yoy, almost in-line with our expectation of Rs155cr for 4QFY2012. The growth for the quarter came in mainly on back of exports, which grew by 49.0% yoy. The domestic formulations, which accounted by 55.5%, grew by 13.4% yoy. Gross margin came in at 56.1%, in-line with expectations of 55.8%. Also, the OPM expanded by 170bp yoy to 14.6% (12.9%), just-in-line our estimates. Net profit for the quarter came in at Rs12.5cr, 21.9% below our estimate of Rs16cr.”

“We expect net sales to post a 22.3% CAGR to Rs837cr and EPS to post a 33.3% CAGR to Rs8.9 over FY2012-14E. At Rs54, the stock is trading at 7.0x and 5.9x FY2013E and FY2014E earnings, respectively. We recommend Buy on the stock with a revised target price of Rs82,” says Angel Broking research report.   

FIIs holding more than 30% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment

Read More